By Barrett Seaman Tarrytown-based Regeneron Corporation announced on Monday that it has launched a clinical program to evaluate the effectiveness of Kevzara® (sarilumab) as a treatment for severe COVID-19 infections. The double-blind Phase 2/3 trial plans to enroll 400 patients around the country, starting in New York, and test its effect on fever and oxygen deprivation caused by the virus. The second phase of the study, according to the company, “will evaluate the improvement in longer-term outcomes including preventing death […]
The post Regeneron in Trials with Potential COVID-19 Treatment appeared first on The Hudson Independent.